Innoviva Can Offer 25% Upside From Current Levels

We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near $12 currently and it is, in fact, down 17% from its pre-Covid high of $15 in February 2020 - just before the coronavirus pandemic hit the world...